Participant flow25

How many started, completed or left each group, period by period.

1 to 20 of 25

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	233
Overall Study	STARTED	Tanezumab 5 mg	233
Overall Study	STARTED	Tanezumab 10 mg	298
Overall Study	STARTED	Tanezumab 20 mg	297
Overall Study	STARTED	Naproxen 500 mg	298
Overall Study	Treated	Placebo	230
Overall Study	Treated	Tanezumab 5 mg	232
Overall Study	Treated	Tanezumab 10 mg	295
Overall Study	Treated	Tanezumab 20 mg	295
Overall Study	Treated	Naproxen 500 mg	295
Overall Study	Completed Treatment	Placebo	128
Overall Study	Completed Treatment	Tanezumab 5 mg	146
Overall Study	Completed Treatment	Tanezumab 10 mg	193
Overall Study	Completed Treatment	Tanezumab 20 mg	188
Overall Study	Completed Treatment	Naproxen 500 mg	185
Overall Study	COMPLETED	Placebo	23
Overall Study	COMPLETED	Tanezumab 5 mg	18
Overall Study	COMPLETED	Tanezumab 10 mg	19
Overall Study	COMPLETED	Tanezumab 20 mg	22
Overall Study	COMPLETED	Naproxen 500 mg	27

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00876187/flow